Adagene (NASDAQ:ADAG) Stock Price Up 0.8% – What’s Next?

Adagene Inc. Sponsored ADR (NASDAQ:ADAG)’s share price traded up 0.8% on Monday . The stock traded as high as $3.81 and last traded at $3.62. 98,009 shares were traded during trading, a decline of 73% from the average session volume of 362,812 shares. The stock had previously closed at $3.59.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ADAG shares. Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a research note on Friday. Guggenheim reiterated a “buy” rating and issued a $10.00 target price on shares of Adagene in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adagene presently has a consensus rating of “Buy” and a consensus price target of $8.00.

Adagene Price Performance

The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.03. The company’s fifty day moving average is $3.78 and its 200-day moving average is $3.38.

Hedge Funds Weigh In On Adagene

Institutional investors have recently modified their holdings of the stock. Marex Group plc acquired a new position in shares of Adagene in the 2nd quarter valued at about $47,000. Exome Asset Management LLC acquired a new stake in Adagene during the fourth quarter worth about $2,004,000. Citadel Advisors LLC acquired a new stake in Adagene during the third quarter worth about $80,000. SmartHarvest Portfolios LLC purchased a new position in Adagene during the fourth quarter valued at approximately $73,000. Finally, Renaissance Technologies LLC purchased a new position in Adagene during the first quarter valued at approximately $135,000. Hedge funds and other institutional investors own 9.51% of the company’s stock.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.